Table 2 Distribution of demographic and tumor characteristics of stages 1–3 first primary invasive breast cancer by socioeconomic status: California Cancer Registry 2000–2010*
Socioeconomic status category | |||||
|---|---|---|---|---|---|
Lowest/least affluent | Intermediate | Highest/most affluent | Total | ||
N (%) | 49,868 (27.8%) | 37,128 (20.7%) | 92,147 (51.36%) | 179,143 | |
Year at diagnosis | |||||
2000-2006 | n | 31,380 | 23,844 | 59,359 | 114,583 |
% within SES | 62.9% | 64.2% | 64.4% | 64.0% | |
2007-2010 | n | 18,488 | 13,284 | 32,788 | 64,560 |
% within SES | 37.1% | 35.8% | 35.6% | 36.0% | |
Race/ethnicity | |||||
White | n | 25,016 | 25,283 | 70,136 | 120,435 |
% within SES | 50.2% | 68.1% | 76.1% | 67.2% | |
Black | n | 5,454 | 2,349 | 2,834 | 10,637 |
% within SES | 10.9% | 6.3% | 3.1% | 5.9% | |
Hispanic | n | 14,848 | 5,756 | 7,776 | 28,380 |
% within SES | 29.8% | 15.5% | 8.4% | 15.8% | |
API | n | 4,550 | 3,740 | 11,401 | 19,691 |
% within SES | 9.1% | 10.1% | 12.4% | 11.0% | |
Age (years) at diagnosis | |||||
<35 | n | 1,347 | 713 | 1,628 | 3,688 |
% within SES | 2.7% | 1.9% | 1.8% | 2.1% | |
35-69 | n | 35,557 | 25,924 | 66,589 | 128,070 |
% within SES | 71.3% | 69.8% | 72.3% | 71.5% | |
70-79 | n | 8,414 | 6,708 | 15,388 | 30,510 |
% within SES | 16.9% | 18.1% | 16.7% | 17.0% | |
80-89 | n | 4,022 | 3,349 | 7,565 | 14,936 |
% within SES | 8.1% | 9.0% | 8.2% | 8.3% | |
90+ | n | 528 | 434 | 977 | 1,939 |
% within SES | 1.1% | 1.2% | 1.1% | 1.1% | |
AJCC stage | |||||
Stage 1 | n | 21,814 | 18,066 | 47,655 | 87,535 |
% within SES | 43.7% | 48.7% | 51.7% | 48.9% | |
Stage 2 | n | 21,082 | 14,776 | 35,550 | 71,408 |
% within SES | 42.3% | 39.8% | 38.6% | 39.9% | |
Stage 3 | n | 6,972 | 4,286 | 8,942 | 20,200 |
% within SES | 14.0% | 11.5% | 9.7% | 11.3% | |
ER/PR/HER2 subtype | |||||
ER+/PR+/HER2- | n | 18,434 | 15,088 | 40,900 | 74,422 |
% within SES | 52.6% | 56.6% | 59.8% | 57.2% | |
ER+/PR+/HER2+ | n | 3,521 | 2,519 | 6,204 | 12,244 |
% within SES | 10.0% | 9.5% | 9.1% | 9.4% | |
ER+/PR-/HER2- | n | 3,264 | 2,548 | 6,702 | 12,514 |
% within SES | 9.3% | 9.6% | 9.8% | 9.6% | |
ER+/PR-/HER2+ | n | 1,180 | 856 | 2,082 | 4,118 |
% within SES | 3.4% | 3.2% | 3.0% | 3.2% | |
ER-/PR+/HER2- | n | 285 | 212 | 527 | 1,024 |
% within SES | 0.8% | 0.8% | 0.8% | 0.8% | |
ER-/PR+/HER2+ | n | 167 | 120 | 226 | 513 |
% within SES | 0.5% | 0.5% | 0.3% | 0.4% | |
ER-/PR-/HER2- | n | 5,454 | 3,550 | 7,821 | 16,825 |
% within SES | 15.6% | 13.3% | 11.4% | 100.0% | |
ER-/PR-/HER2+ | n | 2,744 | 1,753 | 3,941 | 12.9% |
% within SES | 7.8% | 6.6% | 5.8% | 8,438 | |
Tumor grade | n | 9,276 | 7,998 | 22,058 | 39,332 |
Grade I | % within SES | 19.9% | 22.9% | 25.3% | 23.3% |
n | 18,814 | 14,625 | 37,837 | 71,276 | |
Grade II | % within SES | 40.3% | 41.9% | 43.4% | 42.3% |
n | 17,586 | 11,572 | 25,888 | 55,046 | |
Grade III | % within SES | 37.7% | 33.2% | 29.7% | 32.6% |
n | 1,001 | 698 | 1,344 | 3,043 | |
Grade IV | % within SES | 2.1% | 2.0% | 1.5% | 1.8% |